Discovery through Partnership | Excellence through Quality
| Product Name | Leflunomide |
| Description |
Immunosupressant |
| Purity | >98% (TLC: 5:95, CH3OH/CH2Cl2; Rf=0.65); NMR (Conforms) |
| CAS No. | 75706-12-6 |
| Molecular Formula | C12H9F3N2O2 |
| Molecular Weight | 270.21 |
| Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Properties
| Storage Temperature | -20ºC |
| Shipping Temperature | Shipped Ambient |
| Product Type | Inhibitor |
| Solubility | May be dissolved in DMSO (30 mg/ml); or Ethanol (27 mg/ml) |
| Source | Synthetic |
| Appearance | White crystalline solid |
| SMILES | CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F |
| InChI | InChI=1S/C12H9F3N2O2/c1-7-10(6-16-19-7)11(18)17-9-4-2-8(3-5-9)12(13,14)15/h2-6H,1H3,(H,17,18) |
| InChIKey | VHOGYURTWQBHIL-UHFFFAOYSA-N |
| Safety Phrases |
Classification: Caution: Substance not yet fully tested. Safety Phrases: S22 - Do not breathe dust S24/25 - Avoid contact with skin and eyes S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection Risk Phrases: R25 – Toxic if swallowed R62 – Possible risk of impaired fertility R63 – Possible risk of harm to the unborn child Hazard Phrases: H301 – Toxic if swallowed. H315 – Causes skin irritation. H319 – Causes serious eye irritation H335 – May cause respiratory irritation Precautionary Phrases: P264 – Wash hands thoroughly after handling P280 – Wear protective gloves/protective clothing/eye protection/ face protection P301+310 - IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician P308+313 - If exposed or concerned: Get medical advice/attention |
| Cite This Product | Leflunomide (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-368) |
Biological Description
| Alternative Names | 5-methyl-N-[4-(trifluoromethyl) phenyl]-isoxazole-4-carboxamide |
| Research Areas | Cell Signaling, Neuroscience |
| PubChem ID | 3899 |
| Scientific Background | Leflunomide is an Immuno-suppressant, it inhibits de novo synthesis of pyrimidine nucleotides and the activity of the protein kinase. It is a part of the known “disease-modifying anti-rheumatic drugs” (DMARD). It has been suggested that leflunomide modulates the expansion of activated autoimmune lymphocytes acting on the regression of rheumatoid conditions (1-2). It has been shown to have a double mechanism of action by slowing down and relieving the pain of rheumatoid arthritis. Studies have shown the lethal effects of Leflunomide after administration to mice in various doses (3). |
| References |
1. Fukushima R., Kanamori S., Hirashiba M., et al. (2007) Reprod. Toxical. 24(3-4): 310-316. 2. Smolen JS., Emery P. (2000) Rheumatology. 39: 48-56. 3. Fox R.I., Herrman M.L., Franqou C.G., Wahl G.M., Morns R.E., Strand V. and Kirschbaum B.S. (1999) Clin Immunol 93(3): 198-208. |
Product Images
Chemical structure of Leflunomide (SIH-368), a Immunosupressant. CAS #: 75706-12-6. Molecular Formula: C12H9F3N2O2. Molecular Weight: 270.21 g/mol.
Powered by Bioz
Reviews
There are no reviews yet.